Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic agents (AAs) have been recommended as the first-line systemic treatment for unresectable hepatocellular carcinoma (uHCC). However, most Phase III clinical trials have excluded patients with Child-Pugh B (CP B) cirrhosis. This study aimed to evaluate the efficacy and safety of ICIs combined with AAs in uHCC patients with CP B cirrhosis and compare the outcomes with those in patients with Child-Pugh A (CP A) cirrhosis.

Methods

The uHCC patients who received ICIs plus AAs between September 2020 and November 2024 at Beijing You 'an Hospital were retrospectively analyzed. Tumor response and treatment related adverse events (TRAEs) were compared between the patients with CP A and CP B cirrhosis to assess t

SUBMITTER: Liu D 

PROVIDER: S-EPMC12560343 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature